5-MeO-DMT Analogs With 5-HT1A Selectivity for Reduced Hallucination
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing research has focused primarily on the 5-HT2A receptor for psychedelic drug development, neglecting the role of the 5-HT1A receptor in the therapeutic effects of 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT), despite its potential in treating neurological, psychiatric, and substance use disorders.
Innovation Solution
Development of 5-HT1A-selective analogs of 5-MeO-DMT that activate or selectively activate the 5-HT1A receptor, or simultaneously activate both 5-HT1A and 5-HT2A receptors, for treating neurological, psychiatric, and substance use disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If 5-MeO-DMT and classic psychedelics are used to treat neurological and psychiatric disorders, then rapid and sustained anxiolytic and antidepressant effects are achieved, but hallucinogenic side effects occur
Solution Approach 1:
The patent segments the therapeutic effects from the harmful effects by developing analogs that selectively target the 5-HT1A receptor responsible for therapeutic benefits while avoiding the 5-HT2A receptor that mediates hallucinogenic effects. This is achieved through structural modifications to the 5-MeO-DMT molecule, creating compounds with differential receptor selectivity profiles.
Solution Approach 2:
The patent applies local quality by modifying specific regions of the 5-MeO-DMT molecular structure (such as the N-substituents and indole ring substitutions) to alter receptor binding characteristics. These localized structural changes enable selective activation of 5-HT1A receptors while minimizing interaction with 5-HT2A receptors, thereby maintaining therapeutic efficacy while reducing hallucinogenic potential.
2Loss of information
If research focuses primarily on the 5-HT2A receptor for psychedelic drug development, then mechanisms of action are better understood, but the role of the 5-HT1A receptor in therapeutic effects is neglected
Solution Approach 1:
The patent inverts the conventional research approach by shifting focus from the extensively studied 5-HT2A receptor to the underexplored 5-HT1A receptor. Instead of continuing to develop 5-HT2A-selective compounds, the invention deliberately targets 5-HT1A receptors through analog design, thereby uncovering previously neglected therapeutic mechanisms while reducing reliance on hallucinogenic pathways.
Solution Approach 2:
The patent changes the key parameter of receptor selectivity by designing analogs with optimized 5-HT1A binding affinity and 5-HT2A selectivity ratios. Through systematic modification of molecular parameters (such as N-methyl groups, indole substitutions, and side chain lengths), the compounds achieve enhanced therapeutic profiles by preferentially activating 5-HT1A-mediated antidepressant and anxiolytic pathways.
Data Source
AI summary
Disclosed are compounds having the structure:whereinZ1 is NR4, O, or S;Z2 is CR7 or N;n is 1 to 5;R1 is —H, halogen, —O-alkyl, or together with R2 forms —O—CH2—O—;R2 is —H, —OH, —O-alkyl, —O-alkyl-aryl, —S-alkyl, —S-alkyl-aryl, or together with R1 or R3 forms —O—CH2—O—;R3 is —H, —O-alkyl or together with R2 forms —O—CH2—O—;R4 is H or alkyl;R5 and R6 are each independently H, alkyl, alkenyl, alkynyl or NR5R6 together form a substituted or unsubstituted heterocycle, wherein the heterocycle may be monocyclic or bicyclic,R7 is H or alkyl;wherein R1 is F, when R2 is —O-(n-propyl) or when at least one of R5 or R6 is H, andwherein the compound is other than a compound whereZ1 is NR4 and R1, R2, R3, and R8 are H;n is 2, R1 is halogen, R2 is —OCH3, R3 is —H, R4 is —H, and R5 and R6 are both methyl;n is 2, R1 is —F, R2 is —OCH3, R3 is —H, R4 is —H, and NR5R6 together are —N-pyrrolidine;n is 2, R1 and R2 together forms —O—CH2—O—, R3 is —H, R4 is —H, and R5 and R6 are both methyl; andn is 2, R1 and R2 together forms —O—CH2—O—, R3 is —H,R4 is —H; and R5 and R6 are both isopropyl,or a pharmaceutically acceptable salt thereof.Also disclosed are processes for synthesizing the compounds, and methods for activating or selectively activating the 5HT1A receptor, or of simultaneously activating the 5HT1A and 5HT2A receptors, and of treating a subject afflicted with a neurological disease, psychiatric disorder, or substance use disorder, using the compounds.